NCT04340349

Low-dose Hydroxychloroquine and Bromhexine: a Novel Regimen for COVID-19 Prophylaxis in Healthcare Professionals

Low-dose Hydroxychloroquine and Bromhexine: a Novel Regimen for COVID-19 Prophylaxis in Healthcare Professionals (ELEVATE Trial)

• Status: Unknown
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 214 (estimated)
• Sponsor: Instituto Nacional de Rehabilitacion · Other Government
• Sex: All
• Age: 18 Years – 59 Years
• Healthy volunteers: Accepted

Summary

This study will investigate the security and efficacy of a daily low dose of hydroxychloroquine and Bromhexine, in preventing the development of the disease from COVID-19 in Health Care Workers at a National Institute of Health In Mexico City.

Detailed description

This study will combine two drugs (hydroxychloroquine and Bromhexine) to see if hydroxychloroquine is better in combination with Bromhexine in preventing the development of the disease from COVID-19 in Health Care Workers at a National Institute of Health In Mexico City. Hydroxychloroquine will be used in a low dose (200 mg every 24 hrs). Bromhexine will be 8mg every 8 hrs. The study groups will be the following: 1) HCQ 200mg/d + BHH placebo 2) HCQ placebo plus BHH placebo

Conditions

• Hydroxychloroquine
• Antimalarials
• Enzyme Inhibitors
• Antirheumatic Agents

Interventions

Type	Name	Description
DRUG	Hydroxychloroquine Sulfate	A daily low dose of Hydroxychloroquine Sulfate. Increase the endosomal pH and inhibits of ACE2 glycosylation receptor.
DRUG	Bromhexine 8 MG	TMPRSS2 blocker

Timeline

• Start date: 2021-02-01
• Primary completion: 2021-05-30
• Completion: 2021-06-30
• First posted: 2020-04-09
• Last updated: 2021-06-29

Locations

1 site across 1 country: Mexico